Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS

Next Previous
X
Search
Trial Profile

PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Bladder cancer; Cholangiocarcinoma; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KAMELEON
  • Sponsors Roche

    • Most Recent Events

    • 22 Jul 2019 Planned End Date changed from 31 Mar 2018 to 10 Apr 2018.
    • 22 Jul 2019 Planned primary completion date changed from 31 Mar 2018 to 10 Apr 2018.
    • 02 May 2018 This trial has been completed in Spain end date (2018-04-09).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top